低级别浆液性卵巢癌:科学现状综述
2019年1月,基础、转化和临床研究者及患者倡导者在迈阿密召开会议,讨论低级别浆液性卵巢或腹膜癌的科学现状。该罕见亚型可原发或继发于浆液性交界性肿瘤。综述从流行病学与患者结局、病理学、转化研究、患者护理与临床试验、患者视角五方面总结,旨在推动多中心合作、统一数据库平台及未来临床试验。
要点
- 低级别浆液性卵巢癌罕见,可原发或继发于浆液性交界性肿瘤。
- 综述涵盖流行病学、病理、转化研究、临床 trial 和患者视角五领域。
- 会议目标为启动跨机构合作、统一数据库和未来临床试验。
核心结论
- 需通过多中心合作、统一数据库平台和临床试验推进低级别浆液性卵巢癌的认知与临床诊疗。
研究设计与样本
- 2019年1月于美国迈阿密召开的基础、转化、临床研究者及患者倡导者会议,综述五个领域科学现状。
主要发现
- 低级别浆液性卵巢或腹膜癌为罕见亚型,可原发或继发于浆液性交界性肿瘤。
- 综述涵盖流行病学与患者结局、病理学、转化研究、患者护理与临床试验、患者视角五方面。
临床怎么用
- 倡导跨学术机构合作,建立统一数据库平台,开展实验室研究和临床试验以改善诊疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade serous carcinoma of the ovary or peritoneum-a rare ovarian cancer subtype that may arise de novo or following a diagnosis of serous borderline tumor. The purpose of the conference was to review current knowledge, discuss ongoing research by established researchers, and frame critical questions or issues for future directions. Following presentations and discussions, the primary objective was to initiate future collaborations, uniform database platforms, laboratory studies, and clinical trials to better understand this disease and to advance clinical care outside the boundaries of single academic institutions. This review summarizes the state of the science in five principal categories: epidemiology and patient outcomes, pathology, translational research, patient care and clinical trials, and patients' perspective.
引用
- Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020. PMID: 31969252. doi:10.1016/j.ygyno.2019.12.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。